Infrastructure for Drug Discovery AI

Drug discovery AI requires formally codified computational protocols: molecular screening criteria, target validation decision trees, compound advancement thresholds (e.g., binding affinity >X nM, selectivity ratio >Y), and repurposing eligibility rules. FDA IND filing requirements and GLP/GCP regulatory standards demand that discovery decisions be formally documented with machine-readable rationale. Without explicit, queryable protocols defining when a compound advances from virtual screening to synthesis, the AI operates without defensible decision logic for regulatory submission.

Drug discovery AI requires systematic capture of molecular screening results, protein structure data, clinical trial outcomes linked to drug-target interactions, and experimental validation results. Template-driven data capture ensures each virtual screening run, docking simulation, and bioassay result is recorded with consistent fields—compound identifier, target, assay type, activity value, and experimental conditions—enabling the AI to learn from historical screening campaigns and improve candidate prioritization accuracy.

Molecular analysis and target identification require formal ontology: Compound entities with SMILES/InChI representations and structural property attributes, Target entities with UniProt IDs and binding site definitions, Drug-Target interaction records with activity values and assay conditions, and Pathway entities linking targets to disease mechanisms. Without formal ontology mapping compound structural features to predicted biological activity and target engagement, the AI can't traverse from molecular structure to therapeutic hypothesis autonomously.

Drug discovery AI requires unified API access to molecular structure databases (PubChem, ChEMBL), protein structure repositories (PDB, AlphaFold), clinical trial outcomes databases (ClinicalTrials.gov, internal trial data), drug-target interaction databases, and patient biomarker data for trial optimization. These diverse data sources must be queryable through a unified access layer enabling the AI to assemble multi-source molecular, biological, and clinical context for compound evaluation without researchers manually retrieving data from each database.

Drug discovery AI models must update when new protein structures are deposited in PDB (AlphaFold updates), when clinical trial outcome data becomes available, or when regulatory guidance changes screening criteria. Event-triggered maintenance—new AlphaFold model release triggers protein structure database update, completed trial outcome publication triggers training data refresh—keeps the discovery AI current with scientific knowledge. Daily streaming isn't required given the research timescale of discovery programs.

Drug discovery AI requires API-based connections between molecular databases, protein structure repositories, clinical trial management systems, internal assay data repositories, and computational chemistry platforms (docking engines, MD simulation tools). These connections enable automated compound screening workflows where the AI retrieves molecular structures, computes docking scores, references clinical precedents, and returns prioritized candidate lists without manual data transfer between tools. The research data ecosystem requires API connectivity rather than the clinical integration platform needed for patient-facing capabilities.